1-(1,4-Dioxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Catalog No. :
ACGRIQ022
CAS No. :
2223004-45-1
Molecular Formula :
C13H21BN2O4
Molecular Weight :
280.13

IUPAC Name:1-(1,4-dioxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

1-(1,4-Dioxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(1,4-Dioxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
IUPAC Name1-(1,4-dioxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Molecular FormulaC13H21BN2O4
Molecular Weight280.13
SMILESCC1(C)C(C)(C)OB(C2=CN(C3OCCOC3)N=C2)O1
InChI KeyBDYTXDZRTZNJOX-UHFFFAOYSA-N
Synonym1H-Pyrazole, 1-(1,4-dioxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;1-(1,4-dioxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
CAS No.2223004-45-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACGRIQ022 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYUSO179 route compound structure diagram
    ACYUSO179269410-08-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGRIQ022 route product structure diagram
    ACGRIQ0222223004-45-1
Inquiry

2. ACGRIQ022 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYUSO179 route compound structure diagram
    ACYUSO179269410-08-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGRIQ022 route product structure diagram
    ACGRIQ0222223004-45-1
Inquiry

Comments (0)